Body Fluid Collection and Diagnostics Market Size, Share and Growth Outlook, 2026

Body Fluid Collection and Diagnostics Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Body Fluid Collection and Diagnostics Market size is forecast to increase from $39.87 Billion in 2026 to $70.06 Billion in 2034 at a CAGR of 7.3% between 2026 and 2034.

The Body Fluid Collection and Diagnostics market report provides detailed analysis and outlook of Body Fluid Collection and Diagnostics segments including By Sample (Blood, Saliva, Urine, Cerebrospinal Fluid), By Product (Instruments, Kits & Consumables, Tests & Services), By Technology (Next Generation Sequencing, Polymerase Chain Reaction, Fluorescence In Situ Hybridization ), By Application (Diagnostics & Monitoring, Therapeutic Decision Making, Prognostics & Screening) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Body Fluid Collection and Diagnostics Industry Overview

Automated Molecular Diagnostics Are Transforming Body Fluid Analysis

The Body Fluid Collection and Diagnostics industry is advancing rapidly as healthcare providers increasingly adopt automated diagnostic technologies capable of delivering faster, more accurate, and scalable analysis of biological fluids. Cerebrospinal fluid, blood, saliva, and other body fluids are becoming critical sources of biomarker information for early disease detection and precision medicine applications. A significant development in the market is the transition of F. Hoffmann-La Roche Ltd into full clinical distribution of its Elecsys pTau217 and total-Tau cerebrospinal fluid molecular assays following FDA clearance. These diagnostic kits operate on fully automated cobas immunoassay analyzers and replace traditional manual optical microscopy counting methods with automated biochemical measurements. The assays are specifically designed to identify early-stage amyloid pathology, supporting improved detection of neurodegenerative conditions through highly standardized laboratory workflows. The increasing adoption of automated molecular assays is enhancing diagnostic consistency, reducing laboratory turnaround times, and strengthening the role of body fluid testing in neurological disease management.

Point-of-Care Technologies Expand Decentralized Diagnostic Capabilities

The growing demand for rapid diagnostics is accelerating innovation in portable body fluid testing platforms. Healthcare systems are increasingly deploying compact diagnostic devices capable of delivering laboratory-quality results directly at the point of care. Techkon expanded this trend through the rollout of a portable diagnostic hardware module engineered to analyze biochemical parameters from micro-volumes of human body fluids. The system utilizes advanced multi-spectral optical sensors to capture cellular characteristics, inflammatory biomarkers, and metabolic indicators at the patient bedside. Such technologies reduce dependence on centralized laboratories and enable clinicians to make faster treatment decisions in emergency care, outpatient settings, and remote healthcare environments. The expansion of portable diagnostic solutions reflects the broader movement toward decentralized healthcare models focused on accessibility, efficiency, and real-time clinical decision support.

Advanced Sample Preservation Supports Precision Medicine Workflows

Sample collection and preservation technologies are becoming increasingly important as liquid biopsy testing and molecular diagnostics gain widespread adoption. Industry leaders including Illumina and Guardant Health have optimized consumer-focused fluid logistics through the introduction of at-home sample preservation kits. These solutions incorporate specialized chemical buffers capable of stabilizing circulating tumor DNA and single-nucleotide polymorphisms within saliva and blood samples during routine transportation. By eliminating the need for strict cold-chain shipping requirements, the technology improves sample integrity while enhancing patient convenience. The advancement of body fluid preservation systems is supporting the expansion of home-based diagnostics, liquid biopsy testing, and precision oncology programs by ensuring reliable molecular analysis from remotely collected specimens.

Body Fluid Collection and Diagnostics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Body Fluid Collection and Diagnostics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Becton, Dickinson and Company (BD), Greiner Bio-One International GmbH, Sarstedt AG & Co. KG, Terumo Corporation, Thermo Fisher Scientific Inc., Danaher Corporation (Beckman Coulter), Roche Diagnostics, Abbott Laboratories, Quest Diagnostics, Labcorp. The Body Fluid Collection and Diagnostics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Body Fluid Collection and Diagnostics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Body Fluid Collection and Diagnostics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Body Fluid Collection and Diagnostics companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Body Fluid Collection and Diagnostics markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Body Fluid Collection and Diagnostics Market Competitive Benchmarking and Company Analysis

Leading companies in Body Fluid Collection and Diagnostics industry include- Becton, Dickinson and Company (BD), Greiner Bio-One International GmbH, Sarstedt AG & Co. KG, Terumo Corporation, Thermo Fisher Scientific Inc., Danaher Corporation (Beckman Coulter), Roche Diagnostics, Abbott Laboratories, Quest Diagnostics, Labcorp. The Body Fluid Collection and Diagnostics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Body Fluid Collection and Diagnostics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Body Fluid Collection and Diagnostics market remains one of the strongest-performing segments in the country.
The US Body Fluid Collection and Diagnostics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Body Fluid Collection and Diagnostics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Body Fluid Collection and Diagnostics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Body Fluid Collection and Diagnostics markets

Canada's strong Body Fluid Collection and Diagnostics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Body Fluid Collection and Diagnostics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Body Fluid Collection and Diagnostics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Body Fluid Collection and Diagnostics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Body Fluid Collection and Diagnostics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Body Fluid Collection and Diagnostics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Body Fluid Collection and Diagnostics market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Body Fluid Collection and Diagnostics sales through 2034

France Body Fluid Collection and Diagnostics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Body Fluid Collection and Diagnostics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Body Fluid Collection and Diagnostics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Body Fluid Collection and Diagnostics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Body Fluid Collection and Diagnostics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Body Fluid Collection and Diagnostics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Body Fluid Collection and Diagnostics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Body Fluid Collection and Diagnostics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Body Fluid Collection and Diagnostics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Body Fluid Collection and Diagnostics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Body Fluid Collection and Diagnostics Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Body Fluid Collection and Diagnostics Market Segmentation

By Sample
Blood
Saliva
Urine
Cerebrospinal Fluid
By Product
Instruments
Kits & Consumables
Tests & Services
By Technology
Next Generation Sequencing
Polymerase Chain Reaction
Fluorescence In Situ Hybridization
By Application
Diagnostics & Monitoring
Therapeutic Decision Making
Prognostics & Screening

Top Companies in Body Fluid Collection and Diagnostics Industry

Becton, Dickinson and Company (BD)
Greiner Bio-One International GmbH
Sarstedt AG & Co. KG
Terumo Corporation
Thermo Fisher Scientific Inc.
Danaher Corporation (Beckman Coulter)
Roche Diagnostics
Abbott Laboratories
Quest Diagnostics
Labcorp

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Biotech and Fermented Ingredient Integration to gain rapid penetration

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025